We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Oral Drug Promising for Breast Cancer

By HospiMedica staff writers
Posted on 09 Apr 2001
In two large, multicenter phase II studies involving more than 230 patients, an oral drug showed a response rate of 20-25% in breast cancer patients who had failed treatment with other drugs. More...
A paper on the drug, published in The Oncologist (2001;6:1), was authored by Dr. Joanne L. Blum, of U.S. Oncology (Dallas, TX, USA).

The drug is an oral, enzymatically activated fluoropyrimidine called capecitabine (Xeloda, Hoffman-La Roche, Basel, Switzerland; www.hoffmanlaroche.com) and mimics another drug (5-fluorouracil) requiring infusion into the vein. In addition to being more convenient for patients and nurses, the drug is activated by an enzyme that is more active in tumors than normal tissue, meaning it can generate more of the drug directly into the tumor, reducing side effects such as hair loss and bone-marrow suppression. Dr. Blum says that additional ongoing clinical trials should help further define the drug's role alone and in combination with other agents.

The Oncologist is a medical journal for doctors treating cancer. Its online edition can be found at www.TheOncologist.com.


Related Links:
Hoffman-La Roche

Gold Member
12-Channel ECG
CM1200B
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hybrid Arch Device
Neo EDE
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.